Labordiagnostik bei metabolischen Knochenerkrankungen – Möglichkeiten und Grenzen

Zusammenfassung

Ein wichtiges Tool in der Diagnostik und Differenzialdiagnostik osteologischer Erkrankungen stellt die Labormedizin dar. So dient das in der S3-Leitlinie Osteoporose empfohlene Basislabor zur Differenzierung zwischen primärer und sekundärer Osteoporose, was aufgrund der therapeutischen Konsequenzen von elementarer Bedeutung ist. Knochenumbaumarker geben zusätzliche Informationen zur Abschätzung der Dynamik des Knochenstoffwechsels. Die Knochenstoffwechselmarker finden vorwiegend als Orientierungshilfe bei der Therapieentscheidung, der Verlaufsbeobachtung unter einer osteospezifischen Medikation und im Compliance-Monitoring Anwendung. Ziel des vorliegenden Beitrages ist die Darlegung der Bedeutung der etablierten osteologischen Labordiagnostik bei metabolischen Knochenerkrankungen im Praxisalltag.

Abstract

Laboratory tests are an important tool in the diagnostic and differential diagnostic investigation of osteologic diseases. As recommended in the German S3 guideline for osteoporosis, a basic laboratory examination is essential for the differentiation between primary and secondary osteoporosis, and of prime importance for initiating an appropriate treatment. Markers of bone turnover may provide additional information regarding the dynamics of bone metabolism. They are mainly used to guide the choice of treatment and the monitoring of treatment response and patient compliance after the initiation of an anti-osteoporosis therapy. This paper aims to describe the significance of the established osteologic laboratory tests for metabolic bone diseases in everyday practice.

Schlüsselwörter

Osteoporose - allgemeines Basislabor - Knochenstoffwechselmarker (Knochenbiomarker)

Key words

osteoporosis - general basic laboratory examinations - markers of bone turnover (bone biomarkers)

• Literatur

• 1 Scharla S. Stellenwert des allgemeinen Labors in der Diagnostik und Verlaufskontrolle der Osteoporose. Osteologie 2015; 24: 211-214
• 2 Fachinformation Prolia. www.fachkreise.amgen.de
• 3 Scharla S, Lempert U. Case-Report: Hypercalcemia after Vitamin D supplementation with 20.000 IU every two weeks. Osteoporos Int 2013; 24 (Suppl. 01) S322
• 4 Scharla S. Tumorhyperkalzämie. Nieren- und Hochdruckkrankheiten 2013; 42: 445-450
• 5 Fuleihan GE, Bouillon R, Clarke B. et al. Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. J Bone Min Res 2015; 30: 1119-1133
• 6 Scharla S, Lampert U. Variabilität der 25-Hydroxyvitamin D-Bestimmung in Abhängigkeit der Methodik. Osteologie 2012; 21: A48-A49
• 7 Vanbillemont G, Bogaert V, De Bacquer D. et al. Polymorphisms of the SHGB gene contribute to the interindividual variation of sex steroid hormone blood levels in young, middle-aged, and elderly men. Clin Endocrinol 2009; 70: 303-310
• 8 Crabbe P, Bogaert V, De Bacquer D. et al. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab 2007; 92: 3604-3610
• 9 Van der Veer E, van der Goot W, de Monchy JGR. et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012; 67: 431-439
• 10 Delmas PD, Eastell R, Garnero P. et al. Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000; 11 (Suppl. 06) S2-S17
• 11 Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999; 45 8 Pt 2 1359-1368
• 12 Halleen JM, Alatalo SL, Janckila AJ. et al. Serum tartrate-resistand acid Phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2011; 47: 597-600
• 13 Biegelmayer C, Dimai HP, Gasser RW. et al. Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group. Wien Med Wochenschr 2012; 162: 464-477
• 14 Schwetz V, Obermayer-Pietsch B. Knochenumbaumarker. Übersicht und klinische Bedeutung. Osteologie 2015; 24: 215-218
• 15 Obermayer-Pietsch B, Schwetz V. Biochemische Marker des Knochenstoffwechsels und ihre Bedeutung. Z Rheumatol 2016; 75: 451-458
• 16 Akesson K, Kakonen SM, Josefsson PO. et al. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab 2005; 23: 30-35
• 17 Bauer DC, Sklarin PM, Stone KL. et al. Biochemical markers of bone turnvover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999; 14: 1404-1410
• 18 Lenora J, Ivaska KK, Obrant KJ. et al. Prediction of bone loss using biochemical markers of bone turnover. Osteoporosis Int 2007; 18: 1297-1305
• 19 Garnero P, Sornay-Rendu E, Claustrat B. et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536
• 20 van Daele PL, Seibel MJ, Burger H. et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 1996; 312: 482-483
• 21 Black DM, Delmas PD, Eastell R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822
• 22 Saag K, Lindsay R, Kriegman A. et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007; 40: 1238-1243
• 23 Bauer DC, Garnero P, Hochberg MC. et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21: 292-299
• 24 Cummings SR, San Martin J, McClung MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
• 25 Naylor KE, Jacques RM, Paggiosi M. et al. Response of bone turnover markers to three oral Bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 2015;
• 26 Black DM, Schwartz AV, Ensrud KE. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Longterm Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-2938
• 27 Black DM, Reid IR, Boonen S. et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243-254